JAZZ Pharma’s Ziihera Poised to Redefine Standard of Care for HER2+ Gastroesophageal Adenocarcinoma, Phase 3 Results Show
Market Chameleon (Tue, 18-Nov 11:11 AM)
Jazz Pharmaceuticals Announces Groundbreaking Phase 3 Results for Ziihera—Potential New Standard in HER2+ Gastroesophageal Cancer
Market Chameleon (Mon, 17-Nov 10:35 AM)
JAZZ’s Ziihera Sets New Benchmark: Phase 3 Results Suggest Major Shift for HER2+ Gastric Cancer Treatment
Market Chameleon (Mon, 17-Nov 7:30 AM)
